clinical trial · NCT06401421
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Exact Sciences Corporation·—·recruiting·n = 1,800
Breast CancerctDNA MRD test
brief summary
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
started
Jun 7, 2024
primary completion
Apr 1, 2030
completion
Apr 1, 2030
last updated
Jan 20, 2026
official title
EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol